MedicarePartD.guide

A non-government resource built from CMS public data

Rinvoq on HealthSpring Assurance Rx (S5617-348)

upadacitinib

Covered, with prior authorization required.

Tier 5 (specialty tier). Quantity limit of 168 per 365 days.

$1,538.04
Patient pays / month, after deductible
$1,999.29
Patient pays / month, before the $615.00 deductible
Not offered
Patient pays / 90 days by mail
$0
After the yearly $2,100.00 out-of-pocket cap

RINVOQ 45 mg Tablet, Extended Release at a preferred retail pharmacy, from the plan's negotiated price of $6,152.16 for a month. Other covered strengths are listed below.

Prior authRequired on all 4 covered forms· The plan decides within 72 hours, or 24 if expedited· If denied, the prescriber can ask the plan to reconsider (an appeal)
All 4 covered strengths and forms
FormTierPatient pays / monthLimits
RINVOQ 45 mg Tablet, Extended Release5$1,538.04PA · 168 per 365 days
RINVOQ 15 mg Tablet, Extended Release5$1,703.01PA · 30 per 30 days
RINVOQ 30 mg Tablet, Extended Release5$1,702.61PA · 30 per 30 days
RINVOQ 1 mg/mL Solution5$1,622.31PA · 360 per 30 days

Other JAK inhibitors on this plan

Verify with the plan before prescribing or filling. Member services: (800)222-6700. Data from the CMS 2026 Part D formulary and pricing files. Full plan details

Plan ID s5617-348